Joseph Maakaron - Concepedia

Author

Joseph Maakaron

Also Known As

Alhaj Moustafa, Muhamad, J. E. Maakaron, J. Maakaron, J.E. Maakaron, Joseph E Maakaron, Joseph E. Maakaron, Joseph Maakaron

172

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University of Minnesota The Ohio State University University of Chicago Mayo Clinic in Florida American University of Beirut Medical Center

About

Joseph Maakaron is an author at University of Minnesota specializing in medicine, hematology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	205
2	Health Sciences	4	4	60
3	Cellular Therapies	3	3	47
4	Cell Biology	2	2	72
5	Blood Transplantation	1	1	14

Joseph Maakaron

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity Caron A. Jacobson, Bradley D. Hunter, Robert Redd, Journal of Clinical Oncology	2020	332
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity Caron A. Jacobson, Bradley D. Hunter, Philippe Armand, Blood	2018	85
Hematological manifestations of celiac disease Atallah Baydoun, Joseph Maakaron, Houssam Halawi, Scandinavian Journal of Gastroenterology	2012	56
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Blood Lymphoid NeoplasiaImmunologyCell TransplantationImmune Cell TherapyImmunotherapy	2022	47
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis Joseph Maakaron, Mei‐Jie Zhang, Karen Chen, Bone Marrow Transplantation Hematological MalignancyCardiovascular DiseaseHematologyContemporary Cibmtr AnalysisMedicine	2022	39
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma Frank Cichocki, Bin Zhang, Cheng-Ying Wu, Science Translational Medicine	2023	38
Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma Veronika Bachanová, Dixie Lewis, Joseph Maakaron, Blood	2020	36
Association of CD34 Cell Dose with 5-Year Overall Survival after Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies Timothy D. Gauntner, Claudio G. Brunstein, Qing Cao, Transplantation and Cellular Therapy	2021	31
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma Michael Scordo, Jessica Flynn, Mithat Gönen, Blood Advances	2023	31
A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON). Joseph P. McGuirk, Carlos Bachier, Michael Bishop, Journal of Clinical Oncology Mhc ClassCohort Expansion StudyImmunologyImmunoeditingPathology	2021	25

Page 1